Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Breast Cancer

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 59 articles: HTML format

Single Articles

September 2023
1. CURIGLIANO G, Burstein HJ, Gnant M, Loibl S, et al
   Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.
   Ann Oncol. 2023 Sep 6:S0923-7534(23)00835-9. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   
2. ANDRE F, Su F, Solovieff N, Hortobagyi G, et al
   Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
   Ann Oncol. 2023 Sep 4:S0923-7534(23)00826-8. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   August 2023
3. PARSONS HA, Blewett T, Chu X, Sridhar S, et al
   Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
   Ann Oncol. 2023 Aug 17:S0923-7534(23)00801-3. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   
4. JHAVERI K, Eli LD, Wildiers H, Hurvitz SA, et al
   Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
   Ann Oncol. 2023 Aug 17:S0923-7534(23)00800-1. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   
5. LOIBL S, Azim HA Jr, Bachelot T, Berveiller P, et al
   ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC).
   Ann Oncol. 2023 Aug 9:S0923-7534(23)00798-6. doi: 10.1016/j.annonc.2023.
   PubMed     Abstract available
   
   
   
6. OLIVIER T, Prasad V
   Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer.
   Ann Oncol. 2023;34:723-724.
   PubMed    
   
   
   July 2023
7. TARANTINO P, Tolaney SM, Curigliano G
   Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
   Ann Oncol. 2023 Jul 25:S0923-7534(23)00767-6. doi: 10.1016/j.annonc.2023.
   PubMed    
   
   
   
8. WEI T, Wang D, Yuan P
   The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
   Ann Oncol. 2023 Jul 25:S0923-7534(23)00768-8. doi: 10.1016/j.annonc.2023.
   PubMed    
   
   
   
9. MOSELE F, Di Maio M
   Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit?
   Ann Oncol. 2023;34:567-568.
   PubMed    
   
   
   June 2023
10. VILLACAMPA G, Tung NM, Pernas S, Pare L, et al
    Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
    Ann Oncol. 2023 Jun 9:S0923-7534(23)00721-4. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
11. TARANTINO P, Viale G, Press MF, Hu X, et al
    ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
    Ann Oncol. 2023 Jun 1:S0923-7534(23)00693-2. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    May 2023
12. OLIVEIRA M, Falato C, Cejalvo JM, Vila MM, et al
    Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study.
    Ann Oncol. 2023 May 19:S0923-7534(23)00685-3. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
13. HARBECK N, Fasching PA, Wurstlein R, Degenhardt T, et al
    Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: Primary outcome analysis of the multicenter randomized A
    Ann Oncol. 2023 May 16:S0923-7534(23)00684-1. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
14. CURIGLIANO G, Dunton K, Rosenlund M, Janek M, et al
    Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study.
    Ann Oncol. 2023 May 11:S0923-7534(23)00677-4. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
15. LIPSYC-SHARF M, Tolaney SM
    Elacestrant: who are optimal candidates for the first oral SERD?
    Ann Oncol. 2023;34:449-451.
    PubMed    
    
    
    April 2023
16. GLUZ O, Kuemmel S, Nitz U, Braun M, et al
    Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
    Ann Oncol. 2023 Apr 14:S0923-7534(23)00136-9. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    March 2023
17. KWAPISZ D, Verret B, Garcia C, Andre F, et al
    Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation.
    Ann Oncol. 2023;34:315-318.
    PubMed    
    
    
    January 2023
18. LUEN SJ, Viale G, Nik-Zainal S, Savas P, et al
    Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
    Ann Oncol. 2023 Jan 25:S0923-7534(23)00047-9. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available
    
    
    
19. REICHERT ZR, Morgan TM, Li G, Castellanos E, et al
    Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.
    Ann Oncol. 2023;34:111-120.
    PubMed     Abstract available
    
    
    December 2022
20. CURIGLIANO G, Mueller V, Borges V, Hamilton E, et al
    Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 3
    Ann Oncol. 2022 Dec 21:S0923-7534(22)04773-1. doi: 10.1016/j.annonc.2022.
    PubMed    
    
    
    
21. VAN BAELEN K, Geukens T, Maetens M, Tjan-Heijnen V, et al
    Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785].
    Ann Oncol. 2022 Dec 16:S0923-7534(22)04746-9. doi: 10.1016/j.annonc.2022.
    PubMed    
    
    
    
22. LOVEDAY C, Garrett A, Law P, Hanks S, et al
    Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
    Ann Oncol. 2022;33:1318-1327.
    PubMed     Abstract available
    
    
    November 2022
23. TURNER NC, Swift C, Jenkins B, Kilburn L, et al
    Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer.
    Ann Oncol. 2022 Nov 21:S0923-7534(22)04735-4. doi: 10.1016/j.annonc.2022.
    PubMed     Abstract available
    
    
    
24. BIANCHINI G, Licata L, Viale G, Gianni L, et al
    Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions.
    Ann Oncol. 2022;33:1091-1093.
    PubMed    
    
    
    
25. AUGUSTIN JE, Soussan P, Bass AJ
    Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma.
    Ann Oncol. 2022;33:1134-1148.
    PubMed     Abstract available
    
    
    October 2022
26. SESSA C, Balmana J, Bober SL, Cardoso MJ, et al
    Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    Ann Oncol. 2022 Oct 19. pii: S0923-7534(22)04193.
    PubMed    
    
    
    
27. GEYER CE JR, Garber JE, Gelber RD, Yothers G, et al
    Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
    Ann Oncol. 2022 Oct 10. pii: S0923-7534(22)04165.
    PubMed     Abstract available
    
    
    August 2022
28. LOIBL S, Schneeweiss A, Huober J, Braun M, et al
    Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
    Ann Oncol. 2022 Aug 9. pii: S0923-7534(22)03791.
    PubMed     Abstract available
    
    
    
29. PALUCH-SHIMON S, Cardoso F, Partridge AH, Abulkhair O, et al
    ESO-ESMO 5(th) International Consensus Guidelines for Breast Cancer in Young Women (BCY5).
    Ann Oncol. 2022 Aug 4. pii: S0923-7534(22)01858.
    PubMed     Abstract available
    
    
    June 2022
30. DING K, Chen F, Priedigkeit N, Brown DD, et al
    Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine.
    Ann Oncol. 2022 Jun 25. pii: S0923-7534(22)01734.
    PubMed    
    
    
    May 2022
31. VAN BAELEN K, Geukens T, Maetens M, Tjan-Heijnen V, et al
    Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
    Ann Oncol. 2022 May 20. pii: S0923-7534(22)01167.
    PubMed     Abstract available
    
    
    
32. LOIBL S, Untch M, Burchardi N, Huober J, et al
    Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Onco
    Ann Oncol. 2022 May 17. pii: S0923-7534(22)00676.
    PubMed    
    
    
    
33. MARCZYK M, Mrukwa A, Yau C, Wolf D, et al
    Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
    Ann Oncol. 2022 May 2. pii: S0923-7534(22)00762.
    PubMed     Abstract available
    
    
    April 2022
34. TARANTINO P, Jin Q, Mittendorf EA, King TA, et al
    Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.
    Ann Oncol. 2022 Apr 28. pii: S0923-7534(22)00754.
    PubMed    
    
    
    
35. PICCART MJ, Kalinsky K, Gray R, Barlow WE, et al
    Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082].
    Ann Oncol. 2022 Apr 26. pii: S0923-7534(22)00673.
    PubMed    
    
    
    
36. GEYER CE, Sikov WM, Loibl S
    Reply to the Letter to the Editor "Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer" by A. Okines and N. Turner.
    Ann Oncol. 2022 Apr 4. pii: S0923-7534(22)00671.
    PubMed    
    
    
    March 2022
37. RUGO HS, O'Shaughnessy J, Boyle F, Toi M, et al
    Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study.
    Ann Oncol. 2022 Mar 22. pii: S0923-7534(22)00383.
    PubMed     Abstract available
    
    
    
38. TOMASIK B, Bienkowski M, Jassem J
    Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast.
    Ann Oncol. 2022 Mar 16. pii: S0923-7534(22)00384.
    PubMed    
    
    
    
39. FLEMING GF, Pagani O, Regan MM, Walley BA, et al
    Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00380.
    PubMed    
    
    
    
40. OKINES A, Turner N
    Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer.
    Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00364.
    PubMed    
    
    
    
41. ZANELLI S, Fiorio E, Zampiva I, Zacchi F, et al
    Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona.
    Ann Oncol. 2022 Mar 8. pii: S0923-7534(22)00363.
    PubMed    
    
    
    February 2022
42. GIANNI L, Huang CS, Egle D, Bermejo B, et al
    Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.
    Ann Oncol. 2022 Feb 16. pii: S0923-7534(22)00113.
    PubMed     Abstract available
    
    
    January 2022
43. GEYER CE JR, Sikov WM, Huober J, Rugo HS, et al
    Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.
    Ann Oncol. 2022 Jan 27. pii: S0923-7534(22)00018.
    PubMed     Abstract available
    
    
    
44. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
    Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
    PubMed     Abstract available
    
    
    
45. GAO JJ, Krol D, Narayan P, Cardoso F, et al
    Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(22)00002.
    PubMed    
    
    
    
46. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertu
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(21)04883.
    PubMed    
    
    
    December 2021
47. CURIGLIANO G, Mueller V, Borges V, Hamilton E, et al
    Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.
    Ann Oncol. 2021 Dec 22. pii: S0923-7534(21)04879.
    PubMed     Abstract available
    
    
    
48. TARANTINO P, Burstein HJ, Lin NU, Krop IE, et al
    Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
    Ann Oncol. 2021 Dec 20. pii: S0923-7534(21)04877.
    PubMed    
    
    
    
49. SPRING L, Matikas A, Bardia A, Foukakis T, et al
    Adjuvant abemaciclib for high-risk breast cancer: the story continues.
    Ann Oncol. 2021;32:1457-1459.
    PubMed    
    
    
    November 2021
50. CARDOZO JMNL, Byng D, Drukker CA, Schmidt MK, et al
    Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04829.
    PubMed     Abstract available
    
    
    
51. POGGIO F, Tagliamento M, Ceppi M, Bruzzone M, et al
    Adding a platinum agent to neoadjuvant chemotherapy for triple negative breast cancer: the end of the debate.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04831.
    PubMed    
    
    
    
52. HAN HS, Arun BK, Kaufman B, Wildiers H, et al
    Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04833.
    PubMed     Abstract available
    
    
    
53. EMENS LA, Adams S, Barrios CH, Dieras V, et al
    Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.
    Ann Oncol. 2021 Nov 2. pii: S0923-7534(21)04520.
    PubMed    
    
    
    October 2021
54. HARBECK N, Rastogi P, Shahir A, Johnston S, et al
    Letter to the Editor for "Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study".
    Ann Oncol. 2021 Oct 28. pii: S0923-7534(21)04551.
    PubMed    
    
    
    
55. FUENTES-ANTRAS J, Cescon DW
    PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later.
    Ann Oncol. 2021 Oct 19. pii: S0923-7534(21)04523.
    PubMed    
    
    
    
56. GENNARI A, Andre F, Barrios CH, Cortes J, et al
    ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
    Ann Oncol. 2021 Oct 13. pii: S0923-7534(21)04498.
    PubMed    
    
    
    
57. HE W, Eriksson M, Eliasson E, Grassmann F, et al
    CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
    Ann Oncol. 2021;32:1286-1293.
    PubMed     Abstract available
    
    
    September 2021
58. HARBECK N, Rastogi P, Martin M, Tolaney SM, et al
    Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04494.
    PubMed     Abstract available
    
    
    
59. WANG Y, Acs B, Robertson S, Liu B, et al
    Improved breast cancer histological grading using deep learning.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04486.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: